IQV — IQVIA Holdings Inc.

Sentiment is clearly bullish. Q2 2026 delivered adjusted EPS of $3.15 on revenue of $4.37B (+8.7% YoY), both beats, and management raised FY2026 guidance to $12.80–13.00 adjusted EPS while citing a record backlog near $34.2B. The sell-side is aligned: 36 Buy ratings versus 7 Hold and 1 Sell, with price targets lifted post-Q2 into a $244–$300 range, and the stock responded with a 44% three-month move. Two caveats keep this from being unambiguously euphoric: the stock slipped 2.24% in the week into 2026-09-13 amid macro risk-off and digestion of the $2B 6.375% notes offering priced in early September, and the average analyst target ($237.38 consensus, $245.38 recent average) sits BELOW the $261.77 spot price — the shares have outrun the targets, which is a momentum signal, not a value signal.

Revenue growth is genuinely inflecting upward. YoY revenue growth ran +2.5% (Q1 2025), +5.3% (Q2 2025), +5.2% (Q3 2025), +10.3% (Q4 2025), +8.4% (Q1 2026), +8.7% (Q2 2026) — a clear acceleration off the 2024 trough (+2.3% to +4.3% quarters). The problem is flow-through. Operating income in Q2 2026 was $506M — exactly equal to Q2 2025's $506M — on $351M more revenue, so operating margin fell to 11.6% from 12.6% (-100bps YoY). Q1 2026 was 12.4% vs 12.95% (-57bps) and Q3 2025 was 13.5% vs 14.1% (-63bps). So revenue is accelerating while margins decelerate — that is the single most important tension in these numbers. Free cash flow is steadier: trailing-twelve-month FCF is about $2.03B, roughly flat YoY, but H1 2026 FCF of $851M is up 18% versus H1 2025's $718M, a genuine improvement. Reported EPS is noisy quarter to quarter (Q4 2025's $2.99 and 16.8% margin reflect seasonality, and the source data's $292M Q4 2025 gross-profit line looks like an artifact against $1.3–1.4B in every other quarter). Verdict: revenue trending up, margin trending the wrong way — a mixed picture that is net improving at the top line but not yet at the profit line.

Fair-to-slightly-expensive as of 2026-09-13. At $261.77 the stock trades at 32.2x TTM GAAP EPS of $8.22, but only ~20.2x forward adjusted EPS ($12.90 FY2026 guidance midpoint; $12.968 next-FY consensus) — a large gap created by roughly $1.1B/yr of acquisition-related amortization. PEG on TTM is 1.95. Price/book is 7.09, price/sales 2.54, EV/EBITDA ~16.6x, and FCF yield ~4.7%. Against its own five-year averages (P/E 35.4x, P/S 2.82x) it screens in-line-to-cheap on GAAP earnings and roughly in line on sales — which is why the deterministic model labels valuation "Neutral vs. its own history" (61.9). But on the metrics that matter for cash economics (EV/EBITDA ~16.6x, ~27x EV/FCF for a high-single-digit grower with an 8.2% ROIC), the stock is full, not cheap. It also trades above the average sell-side target.

The market is paying for an operating-leverage story that hasn't hit the P&L yet. Revenue is compounding at 8.7% and the backlog is a record $34.2B, so the top line is doing its job — but operating income is flat YoY, meaning investors are capitalizing margin expansion that is currently still a promise (higher-margin backlog conversion, AI-driven productivity from the NVIDIA-backed IQVIA.ai platform). That is why the stock can run 44% in a quarter while trading above the average analyst target: momentum is pricing the turn before the income statement confirms it. If Q3 2026 shows margin stabilization, 20x forward adjusted EPS holds or expands and the run continues. If revenue growth is being bought with lower-margin pass-through work and the ~100bps margin drag persists, the multiple compresses toward the mid-teens and the stock gives back a chunk of the move. This stock now needs beats, not in-line quarters.

As of 2026-09-13, RSI(14) stood at 60.7 — constructive and trending, not overbought. Price was +1.7% versus the 20-day SMA (~$257), +11.3% versus the 50-day SMA (~$235), and +29.2% versus the 200-day SMA (~$203). That is a firmly established, well-ordered uptrend, but the 29% gap above the 200-day is stretched and, combined with a 2.24% down week and the 52-week high of $271.80 just overhead, argues against chasing here. The cleaner entry zone is a pullback toward the 50-day SMA around $235–$245, which conveniently overlaps my intrinsic-value estimate and the analyst recent-average target. Momentum traders can argue the trend is intact; value-aware buyers should wait for the mean reversion.

• Interest rates and leverage: $13.7B of long-term debt against $1.9B of cash, D/E of 2.63x and a current ratio of 0.71. The September 2026 $2B senior notes priced at 6.375% to retire 5.000% paper removes a near-term maturity wall but permanently raises interest expense; a higher-for-longer rate environment keeps the leveraged balance sheet a discount-rate overhang.
• Biopharma and biotech funding cycle: CRO bookings and backlog conversion are levered to pharma R&D budgets and biotech funding. Client decision timelines have stabilized, but any funding contraction would slow new awards and make the record $34.2B backlog convert more slowly than modeled.
• FDA and clinical-trial regulation: IQVIA executives have engaged legislative subcommittees on streamlining early-stage trial efficiency — a potential structural tailwind for R&D Solutions if trial starts accelerate, but policy or reimbursement reform that squeezes pharma client budgets would cut the other way.
• AI-driven competitive dynamics: the IQVIA.ai platform built with NVIDIA is a differentiator in trial optimization and real-world evidence, but AI also lowers barriers for data-native entrants, which could compress pricing in the higher-margin data and analytics franchise over time.
• Healthcare data privacy regulation: IQVIA's core moat is licensed healthcare data. Tightening consent and data-use rules across US states, HIPAA and GDPR directly attack the asset base that supports the analytics margin.

• Q3 2026 earnings (expected late October / early November 2026): the first hard check on whether raised FY2026 guidance of $12.80–13.00 adjusted EPS is tracking — and, critically, whether the ~100bps YoY operating-margin compression finally stops.
• Backlog conversion: turning the record ~$34.2B backlog into revenue at better margins is the single largest swing factor for 2027 EPS estimates of $12.97.
• Further IQVIA.ai / NVIDIA agentic AI product rollouts and any late-2026 investor day strategy update, which could support a re-rating if productivity gains show up in margins.
• Capital allocation post-refinancing: with ~$2B of annual free cash flow, any acceleration of deleveraging or buyback resumption would address the leverage discount.
• Sell-side target resets: with consensus targets ($237–$245) below the $261.77 spot price, a wave of upward revisions would validate the move; downgrades on valuation would pressure it.

• Margin compression is the biggest one. Q2 2026 revenue rose 8.7% YoY but operating income was flat at $506M, so margin fell ~100bps. If the incremental revenue is low-margin pass-through work and AI productivity savings don't materialize, the $12.97 next-FY EPS estimate is at risk and the multiple with it.
• Balance-sheet leverage: 2.63x debt/equity, 0.71 current ratio, $13.7B long-term debt against $1.9B cash, and a refinancing that raises the coupon to 6.375% from 5.000%. Rising rates hit both earnings and the discount rate applied to them.
• Valuation and momentum reversal risk: up 44.3% in three months and 58.9% in six, trading ~29% above the 200-day SMA and above the average analyst target — the setup is vulnerable to any disappointing print or macro risk-off.
• Structurally low returns on capital: ROIC of 8.2% sits below any reasonable cost of capital, and GAAP EPS ($8.22 TTM) is 36% below adjusted ($12.90 FY2026E) because of amortization from a serial-acquisition model. If M&A is required to sustain growth, adjusted EPS flatters the economics.
• Cyclical biopharma exposure: bookings depend on biotech funding and large-pharma R&D budgets. The 2024 revenue trough (+2% to +4% growth) proved this is a cyclical business, not a pure defensive compounder.

IQVIA is a genuinely improving business — accelerating revenue (+8.7% in Q2 2026), a record $34.2B backlog, raised guidance, ~$2.0–2.1B of annual free cash flow, and cash-backed earnings (accruals ratio -1.01%) — but the stock has already been paid for that improvement, up 44% in three months and now sitting above the average sell-side target at 20x forward adjusted EPS, ~16.6x EV/EBITDA and a 4.7% FCF yield. The missing piece is margin: revenue grew 8.7% while operating income was flat, so the operating leverage investors are capitalizing hasn't appeared. My independent DCF/multiple blend puts intrinsic value near $244 versus $261.77 on 2026-09-13 — modestly overvalued, with the honest caveat that a clean margin turn would justify more. Not a buy at this price; the $235–$245 zone is where the risk/reward improves.

Blended bottom-up DCF and forward-multiple cross-check as of 2026-09-13. DCF: $2.15B FY2026E FCF base (H1 2026 FCF of $851M, +18% YoY, annualized with normal H2 weighting), 8.5% FCF growth for five years, 3.0% terminal growth, and ~8.4% WACC (beta 1.186, ~4.2% risk-free, 4.5% equity risk premium, ~4.9% after-tax cost of debt) yields a ~$51.9B enterprise value; subtracting ~$11.8B of net debt (long-term debt $13.705B less cash $1.909B) over ~164.6M shares gives roughly $244. Cross-check: 19x forward adjusted EPS of $12.90 (FY2026 guidance midpoint) = $245, a multiple that reflects low-double-digit EPS growth but discounts for 2.63x leverage and an 8.2% ROIC — both methods converge near $244, about 7% below the $261.77 price.